Received: 29 March 2025 | Revised: 30 July 2025 | Accepted: 23 October 2025 | Published online: 11 November 2025

Medinformatics
2025, Vol. 00(00) 1–17
DOI: 10.47852/bonviewMEDIN52025796

REVIEW

The Role of Precision Medicine in Family Health: Tailoring Treatments for Hereditary Diseases

Rufus Oluwagbemileke Ajayi[1,*], **Oluwafikayo Seun Adeyemi-Benson**[1], **Oluwateniola Ajoke Adeyemi-Benson**[2,3], **Taiwo Temitope Ogunjobi**[3], **Onyeka Mary Ukpoju-Ebonyi**[1] **and Jean-Marie Akor Ebonyi**[1]

[1]*Department of Public Health, University of Illinois at Springfield, USA*

[2]*Department of Medicine and Surgery, Afe Babalola University, Nigeria*

[3]*Department of Biochemistry, Ladoke Akintola University of Technology, Nigeria*

Abstract: Precision medicine is transforming the management of genetic disorders by facilitating personalized treatment approaches that enhance patient outcomes and tackle familial health issues. This study consolidates recent advancements in genetic testing, targeted pharmacological therapies, and individualized treatment strategies, concentrating on cystic fibrosis, sickle cell anemia, and familial hypercholesterolemia. Significant attention is directed toward the essential functions of early diagnosis, familial risk evaluation, and preventive measures to improve health-related quality of life. The review critically examines ongoing challenges, including healthcare disparities, ethical dilemmas, and data privacy concerns. Additionally, it examines the incorporation of emerging technologies, such as multi-omics platforms, artificial intelligence, and genome editing, as valuable tools to enhance diagnosis, therapy, and disease monitoring. The review highlights the potential of precision medicine to enhance sustainable healthcare systems by improving resource allocation, mitigating the long-term economic impacts of chronic genetic disorders, and promoting equitable access to innovative therapeutics. This review highlights the transformative potential of precision medicine in managing genetic disorders using CRISPR-Cas9 and its alignment with the Sustainable Development Goals, which aim to promote global health equity and personalized care.

Keywords: precision medicine, hereditary diseases, genetic testing, targeted therapies, multi-omics, personalized healthcare

1. Introduction

Hereditary diseases result from genetic mutations or chromosomal aberrations passed down through generations. These diseases may manifest as monogenic disorders, including cystic fibrosis (CF), sickle cell anemia (SCA), and Huntington's disease, or as complex disorders influenced by multiple genes and environmental factors, such as familial hypercholesterolemia (FH) and specific cancer types. Hereditary diseases inflict significant harm on individuals and disrupt familial health dynamics [1]. Family members may experience significant emotional, psychological, and financial distress due to the chronic nature of these disorders and the potential for recurrence in future generations. The psychological stress of caregiving, uncertainty over sickness progression, and concern about passing the ailment to children further increase the impact on families [2]. Additionally, genetic diseases frequently require lifelong medical treatment and treatments, potentially resulting in financial difficulties and restricting access to adequate healthcare in at-risk areas. Early onset and severe phenotypes, as seen in conditions such as Duchenne muscular dystrophy or Tay-Sachs disease, complicate management and highlight the necessity for preventive and therapeutic actions. Moreover, the cultural and societal stigma associated with inherited illnesses may diminish marital opportunities and reproductive choices within affected families, resulting in cycles of stress and discrimination. These issues highlight the necessity for innovative, personalized therapies to alleviate the impact of hereditary diseases on families [3]. Precision medicine is a breakthrough way to treat inherited disorders. It focuses on personalized medicines that are made for each person's unique genetic and molecular makeup. Precision medicine combines modern genetic testing methods, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), with multi-omics approaches to find genetic variants that cause disease and help doctors choose the best treatment. For example, identifying specific cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in CF has enabled the development of tailored medicines, such as CFTR modulators, which significantly improve lung function and quality of life in affected individuals (Figure 1 [4]). One of the key aspects of precision medicine is its capacity to give early diagnosis and risk assessment in asymptomatic family members through genetic screening programs. These initiatives enable identifying at-risk individuals, enabling preventative steps and lifestyle improvements that can postpone or limit illness onset. FH is a striking example, where genetic screening of first-degree relatives enables the early introduction of lipid-lowering drugs, effectively reducing the risk of premature cardiovascular events [5]. Additionally, precision medicine harnesses emerging technologies such as CRISPR-based

*__Corresponding author:__ Rufus Oluwagbemileke Ajayi, Department of Public Health, University of Illinois at Springfield, USA. Email: Gajay2@uis.edu



Figure 1. Overview of precision medicine in family health

genome editing, which holds promise for repairing harmful mutations at their source. While still in their earliest phases, these technologies have shown value in preclinical research for genetic disorders such as SCA and beta-thalassemia, presenting hope for curative medicines. Artificial intelligence (AI) and machine learning (ML) are also vital to precision medicine, advancing the development of predictive models to detect genotype-phenotype links and expand therapeutic options [6]. Despite its potential, the adoption of precision medicine faces barriers, including the high expense of genetic testing, limited access in resource-poor places, and ethical problems associated with genetic privacy and prejudice. Addressing these difficulties requires coordinated efforts to promote equitable access to precision medicine and to establish sound regulatory frameworks that protect patients and their families. Precision medicine can improve the care of genetic illnesses by fostering interdisciplinary collaboration among doctors, researchers, and policymakers, relieving their burden on family health and providing individualized healthcare solutions [7]. Precision medicine improves patient outcomes via individualized therapy alternatives. It supports sustainable development by increasing the effective use of healthcare resources, reducing the long-term economic impact of inherited illnesses, and promoting health equity [8]. By embracing emerging technologies such as multi-omics, artificial intelligence (AI), and gene editing, precision medicine enables the development of cost-effective therapies that prevent unnecessary treatments and hospitalizations. Furthermore, improving access to genetic screening and tailored treatments supports the overall aims of sustainable healthcare systems, ensuring that medical breakthroughs benefit diverse populations while supporting durable global health resilience [9].

1.1. Objectives of the review

The primary goal of this study is to analyze the revolutionary influence of precision medicine in addressing genetic disorders, with a special focus on its implications for family health. By giving a complete review of significant hereditary illnesses, such as CF, SCA, and FH, the study attempts to address the challenges these diseases pose to afflicted individuals and their families. It recommends studying how these issues might be handled by integrating genetic testing, tailored drugs, and early intervention measures, as informed by precision medicine. Additionally, the study examines the potential of future technologies, such as CRISPR-based gene editing and AI, in boosting individualized therapy for inherited illnesses. The review provides actionable insights for academics, clinicians, and policymakers by exploring the potential and challenges of applying precision medicine across diverse healthcare contexts. Ultimately, it underscores the importance of precision medicine in easing the burden of hereditary disorders and enhancing the well-being of affected families.

1.2. Novelty and originality of the review

The novelty and originality of this work lie in its complete integration of new omics technologies, AI-driven precision medicine, and their ethical implications in the context of biomedical research and healthcare. Unlike past research focusing on individual portions of multi-omics analysis or precision medicine, this work synthesizes recent discoveries across many domains, providing a holistic perspective on how these technologies affect diagnoses, therapy, and disease modeling. A significant feature of this study is its emphasis on real-world applications of AI in multi-omics data interpretation, highlighting emerging ML frameworks that expedite biomarker identification and targeted therapy. Furthermore, this study goes beyond current presentations by addressing computational and reproducibility concerns in multi-omics research, offering insights into solutions such as federated learning, explainable AI, and enhanced data harmonization tools. Additionally, the review provides a novel perspective by incorporating ethical and regulatory challenges that are generally neglected in discussions of AI-driven medicine. This work reveals the broader societal repercussions of developing biomedical technologies by critically examining case studies of genetic privacy breaches, prediction algorithm errors, and inconsistencies in data access. This study highlights extant knowledge by bridging the gap between technological advancement and ethical considerations. It provides a forward-looking analysis of key impediments and potential remedies, thereby advancing the state of the art in biomedical research.

1.3. Research gap

Despite major achievements in multi-omics and AI-enhanced precision medicine, some key gaps still exist. Current research often explores these topics in isolation, failing to give a thorough appraisal of their integration and practical applicability. This research elucidates the relationship between AI and multi-omics in increasing biomarker identification, disease prediction, and the formulation of individualized therapeutics. Furthermore, difficulties such as computational complexity, data homogeneity, and reproducibility are typically recognized but rarely adequately investigated, along with suggested cures. This article examines these weaknesses by investigating creative alternatives such as federated learning, explainable AI, and complex statistical frameworks to promote data integration and interpretability. Moreover, although ethical challenges such as genetic privacy and bias in AI models are generally acknowledged, a concentrated discourse on practical case studies and mitigation approaches remains insufficient. This research addresses the deficiency by presenting particular cases and advocating equitable and transparent procedures in precision medicine.

1.4. Methodology

This narrative review describes recent advancements in precision medicine for genetic disorders. Relevant papers were located by a thorough search of PubMed, Scopus, and Web of Science databases, covering publications from 2013 to 2024. Keywords included "precision medicine," "genetic disorders," "personalized therapy," "genomic medicine," and disease-specific terms like "cystic fibrosis," "sickle cell anemia," and "familial hypercholesterolemia." Studies were chosen based on their relevance to the review goals, with preference given to peer-reviewed publications, clinical trials, systematic reviews, and influential commentary. Exclusion criteria involved non-English articles, editorials without empirical data, and studies not relevant to human health. The synthesis focused on detecting theme commonalities in diagnostic improvements, treatment innovations, and implementation obstacles. Although a formal statistical meta-analysis was not undertaken, the findings were qualitatively assessed to identify developing patterns, knowledge gaps, and the promise of precision medicine to assist sustainable and equitable healthcare initiatives.

2. Precision Medicine in Key Hereditary Diseases

Precision medicine represents a paradigm shift in addressing inherited disorders, utilizing a tailored approach to diagnosis and therapy. Unlike traditional techniques, which frequently employ a one-size-fits-all policy, precision medicine tailors medical interventions based on genetic, environmental, and behavioral characteristics unique to each patient. This individualized approach is particularly transformational in hereditary disorders, where genetic abnormalities play a fundamental role in disease genesis, progression, and response to treatment [8]. Conditions such as CF, SCA, and FH highlight the potential of precision medicine (Table 1). Advances in genetic technologies and biomarker identification have enabled early detection, more precise prognosis, and the creation of targeted therapeutics. This section examines the application of precision medicine in various diseases, highlighting its impact on treatment outcomes, the reduction of familial disease burden, and its potential to enhance the quality of life for patients and their families [10].

Table 1 offers a review of selected hereditary disorders, their associated genetic alterations, prevalence rates, and contemporary precision medicine therapy options. It highlights how genotype-specific therapies, such as CFTR modulators, gene-editing medicines, and targeted lipid-lowering medications, are being deployed to improve disease management and patient outcomes in genetically defined groups.

2.1. Cystic fibrosis

CF, a life-limiting autosomal recessive condition, comes from mutations in the CFTR gene. These mutations impair the CFTR protein, which regulates salt and water transport across epithelial cells, resulting in the development of thick mucus in the lungs, pancreas, and other organs. Advances in understanding the genetic basis of CF have stimulated the development of CFTR mutation-specific therapies, transforming the therapeutic landscape of the disease [11]. One of the most significant advancements in CF management has been the advent of CFTR modulators. These treatments, which include potentiators, correctors, and amplifiers, directly target the underlying molecular abnormalities created by CFTR mutations. For instance, potentiators such as ivacaftor boost the activity of CFTR channels on the cell surface by enhancing chloride transport. In contrast, correctors like lumacaftor and tezacaftor assist the appropriate folding and trafficking of the CFTR protein. The emergence of combination therapy, such as the triple-combination regimen of elexacaftor, tezacaftor, and ivacaftor, has been particularly revolutionary, displaying efficacy in patients with the most common CFTR mutation, F508del, as well as other less prevalent mutations.

Table 1. Overview of hereditary diseases, genetic mutations, and precision medicine therapies

Hereditary disease	Associated mutations	Prevalence	Current precision medicine treatments	Clinical trial phase/FDA status
Cystic fibrosis (CF)	Mutations in the CFTR gene (e.g., F508del)	1 in 2,500–3,500 live births (Caucasians)	CFTR modulators (e.g., ivacaftor, lumacaftor–ivacaftor combinations), symptomatic therapy (e.g., airway clearance procedures)	FDA-approved (ivacaftor: 2012; triple combo elexacaftor/ tezacaftor/ivacaftor: 2019)
Sickle cell anemia (SCA)	Mutation in the HBB gene (Glu6Val substitution)	1 in 365 live births (African-Americans)	Gene-editing therapies (e.g., CRISPR-Cas9 targeting HBB), hydroxyurea, hematopoietic stem cell transplantation	Hydroxyurea: FDA-approved; CRISPR-based therapy (e.g., exa-cel): FDA-approved (2023)
Familial hypercholesterolemia (FH)	Mutations in LDLR, APOB, or PCSK9 genes	1 in 250–500 (heterozygous); 1 in 1,000,000 (homozygous)	PCSK9 inhibitors (e.g., alirocumab, evolocumab), statins, ezetimibe, lifestyle interventions	PCSK9 inhibitors FDA-approved (2015); statins and ezetimibe approved since the 1990s

These drugs have increased therapy options for a broader set of CF patients and considerably improved clinical results [12].

Clinical trials and real-world investigations have indicated that CFTR modulators improve lung function, minimize exacerbations, and promote nutritional status. Triple combination therapy with elexacaftor–tezacaftor–ivacaftor has been reported to raise FEV1 by around 14.3% from baseline in Phase III clinical trials. For example, patients on elexacaftor–tezacaftor–ivacaftor have experienced improvements in forced expiratory volume in one second (e.g., "FEV1 increased by 14.3% in elexacaftor–tezacaftor–ivacaftor trials"), a key indicator of lung function, as well as reductions in sweat chloride levels, a biomarker of CFTR activity [13]. Notably, these drugs also lower hospitalizations and healthcare utilization, underlining their usefulness in relieving the illness load. Beyond clinical metrics, CFTR modulators have considerably helped patients' quality of life. Improvements in respiratory symptoms, physical functioning, and psychological well-being have been frequently observed. By targeting the primary cause of CF at the molecular level, these drugs alleviate the chronic morbidity associated with the condition and allow patients increased life expectancy and better engagement in daily activities [14].

Despite these advancements, challenges remain. The high cost of CFTR modulators limits their accessibility in resource-limited settings, while particular CFTR mutations, such as nonsense mutations, remain untreatable with existing treatments. Furthermore, long-term trials are necessary to determine the continuous efficacy and safety of these treatments over decades. Future research should focus on identifying treatments for currently untreatable mutations, improving affordability, and resolving the ongoing difficulties of CF despite CFTR regulation [15]. In summary, CFTR mutation-specific medicines have transformed the management of CF, converting it from a lethal pediatric disease into a manageable chronic condition for many people. These developments emphasize the importance of precision medicine in addressing inherited diseases, bringing optimism for further advancements that will continue to enhance the lives of CF patients and their families [16].

2.2. Sickle cell anemia

SCA is a severe genetic blood disorder caused by a single-nucleotide mutation in the β-globin gene (HBB), leading to the production of abnormal hemoglobin S (HbS). The polymerization of HbS in deoxygenated environments deforms red blood cells into a sickle morphology, leading to hemolytic anemia, vaso-occlusive crises, and multi-organ impairment. While symptomatic treatments like hydroxyurea and continuous blood transfusions have proved essential in treating the disease, they do not address its core cause. Recent breakthroughs in gene-editing technologies, particularly CRISPR-Cas9, have offered new paths for therapeutic therapies by directly addressing the genetic mutation responsible for SCA [17].

CRISPR-Cas9 has emerged as an innovative technique for genome editing, permitting precise modifications to the DNA sequence. In the context of SCA, gene-editing efforts have focused on two primary approaches: correcting the HBB mutation or reactivating fetal hemoglobin (HbF). HbF, broadly expressed throughout fetal development, is a natural inhibitor of HbS polymerization. Several studies have revealed the capacity of CRISPR-Cas9 to either fix the HBB mutation or disrupt the BCL11A gene, a critical regulator of HbF production in adult erythroid cells. By restoring the generation of functional hemoglobin or raising HbF levels, gene-editing technologies aim to improve or eliminate the clinical signs of SCA [18]. One of the most promising advancements in this sector is the ex vivo technique for gene editing. Hematopoietic stem and progenitor cells (HSPCs) are harvested from the patient, edited using CRISPR-Cas9 to repair the SCA mutation or enhance HbF expression, and then reinfused after undergoing conditioning therapy (Figure 2 [19]). Early clinical trials have shown



Figure 2. Gene therapy approaches for sickle cell disease using CRISPR technology

exceptional success with this method. For example, individuals treated with CRISPR-based editing of BCL11A have demonstrated significant increases in HbF levels, reductions in vaso-occlusive crises, and marked improvements in overall quality of life. These results underscore the transformative potential of gene editing as a therapeutic therapy for SCA [20].

Ex vivo gene therapy relies upon the isolation of patients' HSPCs, their modification, and subsequent infusion of the cellular product after a conditioning phase. The most exploited strategies for this scope are ex vivo gene addition based on virus-mediated delivery of a functional copy of the HBB gene (e.g., lentiglobin), ex vivo genome editing (nuclease-based Homology-Directed Repair (HDR)-mediated correction of the HBB gene), and ex vivo gene editing (nuclease-based Non-Homologous End Joining (NHEJ)-mediated HbF induction). The in vivo gene therapy depends upon direct infusion of the editing machinery to target patient resident HSPCs, without isolation-manipulation-conditioning and re-infusion.

Emerging therapeutic approaches extend beyond CRISPR-Cas9, including base editors, prime editing, and gene therapy. Base editors, which permit single-nucleotide alterations without creating double-strand breaks, are well-suited for fixing the HBB point mutation with remarkable precision and few off-target effects. Prime editing, a newer and even more precise approach, has shown promise in preclinical animals for performing the desired genetic modification with minimal likelihood of undesirable mutations. Meanwhile, standard gene therapy procedures, such as delivering a working HBB gene via lentiviral vectors, are advancing, giving various choices for SCA patients [21]. Despite these substantial breakthroughs, several barriers remain in adopting gene-editing technologies for SCA. The complexity and high expense of ex vivo therapies limit their accessibility, particularly in low- and middle-income countries, where the sickness burden is largest. Additionally, long-term safety concerns, including potential off-target effects and genotoxicity, require thorough consideration through prolonged follow-up studies. The introduction of in vivo gene-editing techniques, which try to change genes directly within the patient's body, shows promise for circumventing these limits by simplifying the therapy procedure and boosting accessibility [22]. The emergence of gene-editing technologies, such as CRISPR-Cas9, presents a paradigm shift in treating SCA, giving a chance for a curative approach to this deadly disease. By addressing the genetic foundations of SCA, these developing medicines promise to reduce patients' suffering and underscore the transformative importance of precision medicine in fighting hereditary disorders. Continued research, ethical considerations, and efforts to provide equitable access are necessary to fully harness the benefits of these revolutionary technologies [23].

2.3. Familial hypercholesterolemia

FH is a common autosomal dominant genetic disorder characterized by markedly high low-density lipoprotein cholesterol (LDL-C) levels, leading to an increased risk of early atherosclerotic cardiovascular disease (ASCVD). The genetic foundation of FH generally contains mutations in the LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/kexin type 9 (PCSK9) genes, which lead to poor clearance of LDL-C from the bloodstream. This genetic defect produces lifelong hypercholesterolemia, demanding early and vigorous therapy to limit the accompanying cardiovascular risks. Advances in mutation-specific medicines, particularly PCSK9 inhibitors, have transformed the treatment of FH, providing a new level of precision in lipid-lowering therapies [10].

PCSK9 inhibitors, such as monoclonal antibodies alirocumab and evolocumab, target the PCSK9 protein, a critical regulator of LDL receptor degradation. PCSK9 generally binds to LDL receptors, facilitating their degradation and lowering their availability to remove LDL-C from circulation. In FH patients with gain-of-function mutations in PCSK9 or those with LDLR mutations, the use of PCSK9 inhibitors has proved revolutionary. By blocking the interaction between PCSK9 and LDL receptors, these treatments promote the recycling of LDL receptors, increasing LDL-C clearance [24]. Clinical trials, including the landmark FOURIER and ODYSSEY OUTCOMES studies, have revealed that PCSK9 inhibitors can reduce LDL-C levels by up to 60% when added to regular statin therapy. The benefit of PCSK9 inhibitors extends beyond lipid-lowering, as these medications also dramatically reduce cardiovascular risks in FH patients. Elevated LDL-C is a well-established risk factor for ASCVD, and long-term exposure to high LDL-C levels in FH accelerates the development of atherosclerotic plaques. By drastically lowering LDL-C levels, PCSK9 inhibitors have been found to minimize the incidence of serious cardiovascular events, such as myocardial infarction, stroke, and cardiovascular death. Notably, the benefits of PCSK9 inhibitors are undeniable in high-risk individuals, such as those with homozygous FH, who demonstrate significant hypercholesterolemia and limited response to standard therapy [25].

Beyond PCSK9 inhibitors, various mutation-specific lipid-lowering treatments have emerged to address the different genetic profiles of FH. For example, lomitapide, a microsomal triglyceride transfer protein inhibitor, decreases LDL-C levels by blocking the assembly and secretion of lipoproteins. Lomitapide has succeeded in homozygous FH patients, where standard therapies generally fail. Similarly, antisense oligonucleotides targeting APOB or ANGPTL3 (e.g., mipomersen and evinacumab, respectively) have significantly decreased LDL-C and triglyceride levels in patients with rare FH subtypes. These targeted treatments give individualized therapy options based on specific genetic mutations, signifying a substantial development in precision medicine for FH. Reducing cardiovascular risks in FH extends beyond medication therapies, including early diagnosis and lifestyle adjustments. Genetic testing plays a significant role in identifying patients with FH, enabling the timely beginning of medication and cascade screening of family members. Combining pharmaceutical therapy with dietary adjustments, regular exercise, and smoking cessation promotes cardiovascular risk reduction [26]. However, mutation-specific medicines' availability and affordability remain challenges, particularly in resource-limited settings. Efforts to address these differences through cost-effective solutions and expanded access to genetic testing are vital to improving outcomes for FH patients globally. Efforts to improve access to mutation-specific medicines are increasingly being addressed through multiple initiatives. Patient assistance programs, often sponsored by pharmaceutical companies and nonprofit organizations, provide financial support, co-pay assistance, and medication donations to eligible patients. The development and approval of generic alternatives have also significantly reduced costs, making essential treatments more affordable.

Table 2 covers essential precision medicine approaches across three main genetic disorders: CF, SCA, and FH. It details the precise therapeutic tactics used, the underlying technology systems that enable tailored care, and the reported clinical outcomes linked to each intervention. Table 2 is aimed to promote a comparative understanding of disease-specific applications of precision medicine and their effects on patient health.

Table 2. Summary of precision medicine interventions in selected genetic disorders

Genetic disorder	Precision medicine intervention	Technological approach	Reported clinical outcomes
Cystic fibrosis	CFTR modulator therapy (e.g., ivacaftor, lumacaftor)	Genotype-guided pharmacotherapy, Genetic testing	Improved lung function, reduced exacerbations, enhanced QoL
Sickle cell anemia	Gene therapy, hydroxyurea dosing guided by pharmacogenomics	CRISPR-Cas9, hematopoietic stem cell editing	Reduced vaso-occlusive crises, increased hemoglobin levels
Familial hypercholesterolemia	PCSK9 inhibitors, statin dose optimization	Genetic screening (LDLR/APOB mutations), polygenic risk scoring	Lowered LDL-C levels, reduced cardiovascular risk

3. Impact on Family Health

Hereditary illnesses significantly impact family health, extending beyond the medical well-being of affected individuals to encompass psychological, social, and economic dimensions. The intergenerational nature of many diseases placed families at the core of risk and resilience, necessitating a holistic approach to care. Precision medicine, with its emphasis on individualized therapy and early diagnosis, offers the potential to limit the impact of chronic diseases on entire families. This section explores how discoveries in precision medicine improve illness management, enhance quality of life, and address the challenges faced by families with genetic abnormalities. Precision medicine enhances patient outcomes by matching interventions to genetic profiles and empowers families with knowledge and solutions to address inherited challenges effectively [27].

3.1. Role of genetic counseling in disease management

Genetic counseling is essential in controlling hereditary disorders, bridging the gap between complex genetic information and its practical use in clinical and familial contexts. With the advent of precision medicine, the necessity of genetic counseling has become even more obvious, as it aids in interpreting genetic test results, analyzing familial risks, and supporting patients and their families in making educated decisions regarding healthcare. Genetic counselors provide a personalized approach to understanding genetic disorders, offering tailored guidance on screening, prevention methods, and therapy alternatives. This individualized guidance is particularly crucial in illnesses with major hereditary components, such as CF, SCA, and FH [28]. One of the key roles of genetic counseling is risk assessment. By studying family histories and genetic testing findings, counselors can identify people and families at heightened risk of inheriting specific genetic illnesses. This information helps at-risk individuals to undergo early diagnostic tests or implement preventative actions. For instance, finding pathogenic mutations in LDL receptor genes in FH allows for early commencement of lipid-lowering medications, considerably reducing the risk of cardiovascular events. Similarly, for families with a history of SCA, counseling aids carrier testing, reproductive decision-making, and early illness intervention [29].

Genetic counseling also provides emotional and psychological aid to patients and families coping with the repercussions of a genetic diagnosis. The disclosure of a hereditary ailment generally causes anxiety, remorse, or concern about the future. Genetic counselors are trained to manage these emotional responses, offering reassurance, coping skills, and clear information about the implications of genetic discoveries. This component of therapy is crucial for families coping with intergenerational disorders, as it helps them manage the emotional complexity of genetic diseases and creates resilience within the family unit [30].

In the era of precision medicine, genetic counseling has developed to include discussions about advanced therapeutic choices, including gene-editing technology and mutation-specific drugs. For example, patients with CF may benefit from counseling sessions that explain CFTR-modulating drugs customized to specific genetic variations. Similarly, for families considering gene-editing approaches, such as CRISPR-Cas9 for SCA, counselors provide essential insights into the benefits, limitations, and ethical implications of evolving technology. By functioning as a bridge between cutting-edge science and patient treatment, genetic counseling ensures that families know how to make decisions matched to their values and medical needs [31]. Moreover, genetic counseling enhances family communication about hereditary risks and disease management. Genetic information can occasionally affect numerous family members and requires open and transparent communication. Counselors aid patients in learning how to communicate their genetic information with family members who may also be at risk. This cascade strategy of testing and prevention can greatly enhance early detection and intervention within families, contributing to improved health outcomes across generations [32].

Finally, genetic counseling examines the ethical, legal, and societal repercussions of genetic testing and disease management. Privacy, genetic discrimination, and informed consent are vital to counseling. Counselors ensure that patients understand the potential hazards of gene testing and are enabled to make autonomous choices about their healthcare [33]. This ethical monitoring is vital in sustaining trust in the healthcare system and guaranteeing fair access to the benefits of precision medicine. In conclusion, genetic counseling is crucial to disease management in hereditary conditions, providing a comprehensive approach that combines risk assessment, psychological support, education, and ethical guidance. As precision medicine improves, genetic counseling will remain vital in translating genomic advancements into meaningful patient treatment and family health improvements [33].

3.2. Early diagnosis and preventive interventions for at-risk family members

The early detection of genetic disorders and the implementation of preventive therapies for at-risk family members are crucial components of modern healthcare, particularly in the development of precision medicine. Hereditary disorders often offer significant hazards across generations, making earlier identification and preventive treatments critical for slowing disease progression and enhancing long-term health outcomes. Early interventions not only address the physical issues provided by genetic abnormalities but also lessen the mental and economic pressures on affected families [34]. Genetic testing is a cornerstone of early diagnosis, which detects harmful variations associated with inherited disorders. Techniques such as whole-genome sequencing (WGS), whole-exome sequencing (WES), and targeted gene panels enable the discovery of disease-causing mutations in individuals before symptoms develop. For example, genetic testing for FH enables the early detection of gene abnormalities, such as those in LDLR, APOB, or PCSK9. Identifying these variants enables early management with lipid-lowering medications, such as statins or PCSK9 inhibitors, which considerably reduces the risk of premature cardiovascular events. Similarly, early genetic screening for CF through newborn screening programs permits fast diagnosis, allowing for the commencement of CFTR-modulating medicines and dietary interventions that improve quality of life and postpone disease progression [35].

Preventive methods extend beyond pharmacological therapies, including lifestyle modifications and routine monitoring of at-risk patients. For instance, in families with a history of hereditary malignancies such as BRCA1/2-associated breast and ovarian cancer, early genetic testing can guide preventative measures, including better surveillance, prophylactic surgeries, or chemoprevention. Similarly, for those having mutations associated with Lynch syndrome, regular colonoscopy screenings can lead to the early diagnosis and excision of precancerous lesions, dramatically reducing the risk of colorectal cancer. Cascade testing, a process that identifies at-risk relatives of patients with proven genetic disorders, is vital in expanding early diagnostic efforts to entire families [36]. This strategy ensures that genetic information is transmitted within families, enabling relatives to estimate their risk and take proactive efforts toward prevention. For example, in SCA, carrier testing in families with a proven history of the disease can identify individuals with sickle cell features, enabling informed reproductive options and planning for prospective health difficulties. Similarly, cascade testing for FH can uncover asymptomatic carriers, enabling the deployment of cholesterol-lowering medications before the appearance of symptoms [37].

In addition to genetic testing, noninvasive prenatal testing (NIPT) has developed as an important approach for the early detection of inherited illnesses. NIPT can detect fetal genetic abnormalities by evaluating cell-free DNA in maternal blood, offering a safe and early way to diagnose illnesses such as Down syndrome, CF, and SCA. Early identification during pregnancy gives parents vital knowledge, enabling them to make informed decisions and the time to arrange for expected medical needs postnatally. Integrating precision medicine techniques with early diagnosis has also allowed for more targeted preventive interventions [38]. Advanced imaging techniques, biomarker assays, and risk prediction models based on genetic and environmental data enable the development of individualized preventative interventions. For example, individuals with a familial vulnerability to cardiovascular illnesses may benefit from personalized lifestyle suggestions, such as dietary changes, exercise regimes, and stress management, informed by genetic and metabolic profiles [39].

Ethical considerations play a significant part in early diagnosis and preventive actions, notably including informed consent, data protection, and the potential psychological impact of genetic information. It is vital for families doing genetic testing to ensure that individuals are properly aware of the implications of test results, both for themselves and their relatives. Genetic counseling works as a vital resource in this situation, delivering emotional support, direction, and clarity on the following measures for at-risk family members. Counseling also helps individuals navigate unpleasant decisions, such as adopting invasive preventive procedures or exposing genetic information to families [40].

Finally, early diagnosis and preventive interventions have important consequences for public health. They minimize the burden of hereditary illnesses on healthcare systems by altering the focus from reactive therapy to proactive prevention. For families, these interventions can help interrupt the intergenerational transmission of hereditary disorders, resulting in healthier outcomes for future generations. Programs to enhance knowledge and accessibility of genetic testing and preventative care are crucial for realizing early intervention's full advantages. Thus, early detection and preventative actions comprise a revolutionary method for regulating genetic illnesses in at-risk families. By using genetic testing, cascade screening, and individualized preventative approaches, these programs empower families to take control of their health, reduce illness risks, and boost quality of life. Integrating ethical considerations with genetic counseling ensures that these benefits are offered ethically and patient-centered, making early intervention a cornerstone of precision medicine [41].

3.3. Implications for multi-generational health

By their very nature, genetic problems have significant implications that spread across several generations within families. Understanding and resolving these implications is critical for breaking the cycle of disease transmission, decreasing associated health risks, and boosting overall family well-being. Precision medicine, focusing on personalized therapies, offers a breakthrough possibility to address multi-generational health by harnessing genetic knowledge to inform proactive interventions. The ripple effects of these programs extend beyond individual patients, changing the health trajectories of entire families and future generations [42]. One of the most profound implications of hereditary illnesses is the intergenerational transmission of genetic risk factors. For example, mutations in the BRCA1 and BRCA2 genes raise the risk of breast and ovarian cancers and are transmitted from parents to children, possibly affecting numerous generations. Similarly, mutations associated with FH, SCA, or CF can perpetuate health concerns within families unless found and managed early. The advent of current genetic testing permits the discovery of these mutations in asymptomatic carriers, offering opportunities for early intervention to avert illness manifestation in future generations. By recognizing genetic risks early, healthcare systems can employ cascade screening, a technique that guarantees genetic testing spreads to at-risk relatives, thereby minimizing the effect of hereditary illnesses across a family tree [43].

Moreover, multi-generational health is directly tied to the psychological and social implications of inherited illnesses. Families with a history of genetic abnormalities generally have heightened anxiety about the future health of their offspring, leading to greater psychological stress. For example, parents aware of their carrier status for disorders like SCA may be anxious about their children's health. These emotional weights could undermine home ties and the general quality of life. Genetic counseling plays a significant role in resolving these challenges by offering families the means to make complex decisions concerning genetic testing, reproductive planning, and disease management [44]. Counseling also helps erase the stigma and fear connected with genetic disorders, fostering a supportive atmosphere for multi-generational health. Advances in precision medicine have also offered new opportunities for multi-generational sickness prevention and control. For instance, the

Table 3. Key benefits of precision medicine for family health

Benefit	Description	Examples
Early diagnosis	Facilitates the identification of genetic predispositions and inherited disorders at an early stage.	Genetic testing for BRCA1/BRCA2 mutations in hereditary breast cancer.
Preventive measures	Facilitates risk-reduction methods for at-risk persons.	Prophylactic procedures, lifestyle adjustments, or focused surveillance.
Personalized treatments	Provides personalized medicines based on individual genetic mutations.	CFTR modulators for cystic fibrosis and PCSK9 inhibitors for hypercholesterolemia.
Improved outcomes	It improves clinical efficacy, disease progression, and quality of life.	Gene-editing tools like CRISPR-Cas9 for sickle cell anemia.
Multi-generational impact	Benefits extend to family members by addressing shared genetic risks.	Cascade screening and early interventions for familial hypercholesterolemia.

development of targeted therapies such as PCSK9 inhibitors for FH or CFTR modulators for CF not only improves the quality of life for current patients but also sets the stage for future generations to benefit from early and effective treatments. These treatments lower the chance of illness development and accompanying difficulties, enabling afflicted persons to lead healthier lives and contribute to a more favorable family health trajectory [24].

Preventive therapies directed to inherited illnesses also play a vital role in multi-generational health. Early interventions, such as increased screening programs for hereditary malignancies or proactive cholesterol control in FH, lower morbidity and mortality rates associated with these conditions. For example, individuals from families with Lynch syndrome, a hereditary susceptibility to colorectal and other cancers, might undergo regular colonoscopies to detect and remove precancerous polyps. Such preventive approaches not only aid the individual but also minimize the emotional and financial strains on their family by reducing the likelihood of advanced-stage illness [45]. Reproductive technologies, such as preimplantation genetic testing, have important consequences for intergenerational health. These methods enable prospective parents with known genetic risks to test embryos for specific mutations, guaranteeing that only unaffected embryos are implanted during in vitro fertilization. This technique effectively prevents the transmission of hereditary disorders to future generations, enabling families to break the cycle of genetic diseases. Additionally, NIPT offers early insights into fetal health, enabling parents to make informed decisions regarding medical management and birth plans, which can positively impact the health of future generations [46].

The implications of genetic diseases on multi-generational health extend beyond biology to include social and economic problems. Families impacted by genetic disorders sometimes endure huge financial hardships due to the cost of medical treatment, genetic testing, and specialized therapies. These charges can perpetuate cycles of economic pressure throughout generations, particularly in low-resource environments where access to healthcare is limited [47]. By investing in precision medicine and genetic counseling programs, healthcare systems may ease these burdens by enabling early diagnosis, minimizing the need for late-stage costly drugs, and empowering families with actionable knowledge. Ethical considerations are also relevant to the debate on multi-generational health. Decisions involving genetic testing, disclosure of results, and reproductive planning must respect individual liberty while assessing the broader ramifications for family members. For example, individuals who test positive for a genetic mutation may confront difficult choices about whether to share this knowledge with their family, who may also be at risk [48]. Genetic counseling can provide crucial support in navigating these ethical challenges, ensuring that families are equipped to make informed decisions that promote individual and communal well-being. In addition, integrating precision medicine into public health policies can potentially boost its impact on intergenerational health. National programs that enhance understanding of genetic testing, subsidize the cost of genetic services, and build registries for inherited illnesses can improve access to life-saving interventions. Such programs ensure that the benefits of precision medicine reach impoverished individuals, fostering justice in healthcare and improving health outcomes across generations [49]. Table 3 outlines the primary benefits of precision medicine in the context of inherited illness management. It underlines how early diagnosis, preventive tactics, customized therapies, and improved clinical outcomes lead to better patient care while also emphasizing the broader impact on family health through multi-generational risk assessment and intervention.

4. Challenges and Ethical Considerations

As precision medicine continues to improve and revolutionize the care of hereditary diseases, different issues and ethical questions arise, particularly in the context of genetic testing and individualized therapy options. While these advancements offer unprecedented prospects for improving patient outcomes, they also bring to the forefront difficult issues involving privacy, accessibility, and the likelihood of discrimination. Integrating genetic information into clinical practice raises questions concerning how such sensitive material is managed, shared, and abused within the healthcare system. Additionally, the rising engagement of gene-editing technologies and reproductive treatments raises ethical questions about modifying the human genome and the long-term repercussions of such activities on individuals and future generations [50].

4.1. Access to genetic testing and precision therapies

Access to genetic testing and precision medications is a cornerstone of modern healthcare, enabling the identification, prevention, and treatment of hereditary diseases with unmatched specificity. Despite major gains in the generation of genetic tools and tailored medications, discrepancies in access continue, driven by economic, geographic, and institutional impediments. Addressing these gaps is critical to realizing the full potential of precision medicine in improving outcomes for individuals and families afflicted by genetic disorders. Genetic testing is crucial for diagnosing hereditary disorders such as CF, FH, and SCA [51]. Advances in genomic technology, notably whole-genome sequencing (WGS) and whole-exome sequencing (WES), have improved the scope and precision of detecting dangerous mutations. However, access to these technologies is sometimes hampered by cost. Comprehensive genetic testing can be too expensive for those without appropriate healthcare or those in low-income environments. For example, while genetic testing for CF has become a standard feature of care in high-resource nations, the prices of WGS or specialty panels generally exceed the budgets of healthcare systems in low- and middle-income countries (LMICs). These economic limits hamper rapid diagnoses and effective therapy, especially where hereditary disorders remain underdiagnosed [52].

Precision medicines, such as CFTR modulators for CF, PCSK9 inhibitors for FH, and forthcoming gene-editing technologies like CRISPR-Cas9 for SCA, illustrate the transformational potential of personalized therapy. These drugs address the underlying genetic causes of diseases rather than merely alleviating symptoms, offering improved clinical results and quality of life. For instance, CFTR modulators like elexacaftor–tezacaftor–ivacaftor have dramatically improved lung function and life expectancy in persons with CF [53]. Similarly, PCSK9 medicines have dramatically cut cholesterol levels and cardiovascular risks in patients with FH. Despite these benefits, their high cost remains a substantial hurdle. Annual expenses for such therapies might approach tens of thousands of dollars, rendering them unavailable to many patients, particularly those in LMICs or underinsured populations in high-income nations [54]. Another key problem is the underrepresentation of various communities in genetic research and medicinal trials. Most genomic databases and research are heavily skewed toward individuals of European ancestry, potentially biasing diagnostic accuracy and the development of treatments. For example, dangerous mutations common in underrepresented cultures may not be adequately detected by standard genetic panels, and treatments may not be adjusted for genetic variation in these groups. This lack of inclusion perpetuates gaps in healthcare outcomes and inhibits the international applicability of precision medicine [55].

To tackle these issues, a multi-pronged approach is required. Policymakers should prioritize integrating genetic services into national healthcare systems, ensuring that genetic testing and precision medications are covered under public insurance schemes. Reducing the cost of gene testing through subsidies, public–private partnerships, and advances in cost-effective technologies is crucial for increasing access. Expanding telemedicine platforms for genetic counseling can expand access to rural and underprivileged groups, spanning geographic gaps [56]. Additionally, improving diversity in genomic research by increasing the involvement of underrepresented communities in genetic studies and clinical trials is crucial for equitable healthcare delivery. Global initiatives, such as those organized by the World Health Organization and the Global Alliance for Genomics and Health, play a significant role in promoting equitable access to genetic services. Collaborative attempts to develop ethical frameworks, standardized processes, and cost-sharing systems can help remove obstacles to access. Moreover, investments in education and training for healthcare practitioners in genomic medicine are vital to ensuring that discoveries in genetic testing and drug development are translated into practical benefits for patients worldwide [57].

4.2. Integration of genomic data into clinical practice

Integrating genomic data into clinical practice offers a significant leap in modern medicine, providing customized disease prevention, diagnosis, and treatment approaches. As the availability of high-throughput sequencing technology continues to rise, turning the quantity of genetic information into useful insights within the clinical environment has become both a goal and a challenge. Effective integration requires resolving technical, infrastructural, and ethical challenges to ensure that genomic medicine becomes a standard component of healthcare delivery [58]. One of the most significant consequences of incorporating genomic data into clinical practice is the capacity to discover genetic predispositions to diseases through predictive testing. For example, genetic screening for BRCA1 and BRCA2 mutations has become a cornerstone in assessing breast and ovarian cancer risk, enabling doctors to propose preventive interventions such as improved surveillance or prophylactic procedures. Similarly, genetic testing for Lynch syndrome enables the identification of patients at elevated risk for colorectal and other malignancies, permitting prompt interventions. By allowing earlier detection and targeted prevention, genomic data improves morbidity and mortality linked to genetic disorders [59].

In addition to risk prediction, genomic data integration has changed the diagnosis of uncommon genetic illnesses, many of which previously defied accurate clinical description. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) have become useful techniques for detecting mitochondrial abnormalities, neurodevelopmental syndromes, and inherited metabolic diseases. For instance, genomic analysis has expedited the discovery of causal mutations in individuals with unexplained developmental delays or epilepsy, leading to more precise diagnoses and the selection of relevant therapy [60]. These developments are particularly impactful in pediatric and neonatal care, where rapid diagnosis can dramatically influence outcomes. Genomic data has also advanced pharmacogenomics, a study that analyzes how genetic variants affect drug response. By incorporating pharmacogenomic information into clinical workflows, healthcare professionals can personalize pharmaceutical regimens to individual patients, boosting therapeutic efficacy while minimizing unwanted effects. For example, genetic polymorphisms in the CYP2C19 gene guide the use of clopidogrel in cardiovascular patients, whereas testing for HLA-B*15:02 can prevent serious adverse responses to carbamazepine in individuals of Asian heritage. The broad implementation of pharmacogenomics promises to optimize pharmacological therapy, reduce healthcare costs, and increase patient safety [61].

Another major application of genetic data integration is in cancer precision therapy. Tumor genomic profiling, such as next-generation sequencing (NGS) of cancer-related genes, has enabled the identification of actionable mutations that guide targeted therapy. For example, finding EGFR mutations in non-small cell lung cancer or HER2 amplification in breast cancer informs the use of tyrosine kinase inhibitors and monoclonal antibodies, respectively. Similarly, thorough genomic sequencing has identified resistance pathways and encouraged the development of second-line medicines, improving clinical outcomes for patients with advanced or refractory malignancies [60]. Despite these benefits, various barriers limit the seamless incorporation of genetic data into clinical practice. One key issue is the interpretation of complicated genomic datasets. Many genetic variations revealed in sequencing studies remain classified as variants of uncertain significance, creating ambiguity in therapeutic decision-making. To address this, constant updates to genomic databases and developments in computational techniques and ML are required to improve variation categorization and pathogenicity prediction [62].

Implementing genomic medicine also requires robust infrastructure, including laboratory facilities for sequencing and bioinformatics tools for data interpretation. Integration efforts are further complicated by the necessity for electronic health records systems to integrate and securely manage huge volumes of genetic information. These technologies must enable smooth data sharing among institutions while preserving patient privacy and data safety. Education and training for healthcare personnel are crucial for the successful integration of genetic data into clinical workflows [63]. Clinicians, genetic counselors, and laboratory professionals must be prepared with the skills to analyze genomic results, explain findings to patients, and implement this information in personalized treatment plans. Interdisciplinary collaboration between geneticists, bioinformaticians, and clinicians is vital for bridging gaps in expertise and guaranteeing effective translation of genomic discoveries. Ethical and regulatory considerations also play a key role in genomic data integration. Issues including informed consent, genetic discrimination, and data ownership must be addressed to develop confidence among patients and clinicians. Policymakers must establish clear criteria for genomic data usage, storage, and sharing to provide an egalitarian and sustainable foundation for genomic medicine [64].

4.3. Ethical concerns regarding genetic privacy and discrimination

Integrating genetic information into clinical practice and research has raised severe ethical difficulties, particularly regarding genetic privacy and the likelihood of prejudice. As genetic data becomes increasingly crucial to healthcare decision-making, it is imperative to address these ethical challenges to safeguard human rights, promote equity, and ensure trust in genomic medicine. Genetic privacy and discrimination issues have far-reaching repercussions, affecting people, families, and society. One of the most severe challenges is the preservation of genetic privacy. Genetic information is intrinsically sensitive, providing predictive insights into an individual's health risks and possible future medical illnesses [48]. This information is extremely personal and individually identifying, heightening the stakes for confidentiality breaches. Unauthorized access to genetic data, whether through hacking, abuse by third parties, or inadequate data security measures, can lead to catastrophic impacts, including psychological anguish, stigmatization, and exploitation. For example, a breach disclosing propensity to conditions like Alzheimer's disease or cancer could create unwarranted fear and hinder life decisions, such as career choices or family planning [65].

Ensuring informed consent is a cornerstone of protecting genetic privacy. Individuals must have the autonomy to decide whether and how their genetic data is used, particularly in research and commercial applications. However, the complexity of genetic data and its likely future application pose hurdles to adequately informed decision-making. Participants in genetic research, for instance, may consent to data usage without fully grasping the ramifications, including secondary discoveries or the possibility of data sharing with third parties. Transparent communication on data usage, storage, and potential risks is vital to preserving ethical norms in genetic research and therapeutic applications [66]. The usage of genetic information by employers and insurance providers presents severe difficulties surrounding genetic discrimination. Without robust legal protections, individuals may suffer discrimination based on their genetic predispositions to specific diseases or conditions. Employers may use genetic data to make employment or promotion decisions, while insurers could reject coverage or boost prices for those thought to have a higher genetic risk. These behaviors not only violate notions of fairness and equality but also prevent individuals from obtaining genetic testing [67].

In some countries, legislation such as the US Genetic Information Nondiscrimination Act (GINA) has been enacted to prevent genetic discrimination in employment and health insurance. However, these restrictions typically have limits, leaving gaps in protections. For instance, GINA does not apply to life insurance, disability insurance, or long-term care insurance, leaving individuals vulnerable to discrimination in these areas. Globally, regulatory frameworks vary widely, with some nations lacking adequate protections, which compounds disparities in access to genetic therapy and its associated benefits [68]. Another ethical difficulty derives from the familial character of gene information. Because genetic data is shared among biological relatives, testing one individual can inadvertently reveal information about others, such as predisposition to hereditary disorders. This raises questions about whether families have a right to know this information and, if so, under what circumstances. For example, should professionals communicate a patient's genetic test results with at-risk family members without the patient's consent? Balancing individual privacy with familial advantage offers a tough ethical dilemma that demands explicit regulations and norms [69].

The storage and sharing of genetic material for research reasons further complicates the ethical context. Genomic databases, both public and private, play a critical role in advancing scientific understanding and developing new treatments. However, these repositories also pose vulnerabilities for data breaches and misuse. The acquisition of genetic data, often connected to clinical and demographic information, raises the likelihood of re-identification, even when the data is anonymized [70]. Additionally, commercializing genetic data by organizations offering direct-to-consumer (DTC) testing raises ethical concerns about profit incentives potentially overriding individual rights and the risk of exploitation by other parties. Emerging technologies, such as AI and ML, provide an extra layer of complexity to ethical dilemmas regarding genetic privacy and prejudice. AI systems rely on vast amounts of genetic data to uncover patterns and make predictions, yet the opacity of these algorithms raises questions about accountability, justice, and potential biases. For instance, algorithmic bias in genomic research could exacerbate health inequities by disproportionately benefiting areas with better representation in genetic datasets, often at the expense of underrepresented groups [71].

4.4. Case studies of genetic data breaches

4.4.1. MyHeritage data breach (2018)

In June 2018, MyHeritage, a popular DTC genetic testing company, revealed a data breach affecting 92 million user accounts. The attack disclosed email addresses and encrypted passwords but did not compromise raw genetic data. However, the event raised concerns about the security of sensitive personal information and highlighted the risks of making massive genetic datasets publicly available. It underlined the need for stronger encryption, enhanced cybersecurity measures, and greater regulatory oversight to preserve genetic privacy [72].

4.4.2. 23andMe data breach (2023)

In October 2023, 23andMe faced a severe security breach in which hackers obtained unauthorized access to customer data through credential stuffing, using credentials stolen from other sites to compromise 23andMe accounts. The breach apparently compromised the genetic ancestry information, health data, and other personal details of thousands of people. This event revealed the weaknesses of DTC genetic platforms, highlighting the importance of multi-factor authentication, strict password policies, and user awareness of data security [73]. These incidents underscore the compelling need for stronger cybersecurity safeguards, robust regulatory frameworks, and ethical oversight in managing genetic information, particularly in precision medicine and multi-omics research.

5. Future Directions

As the field of precision medicine continues to evolve, future advancements promise to modify genetic disease management and boost family health outcomes. The combination of cutting-edge omics technology, AI-driven models, and fair healthcare policy will decide the trajectory of this sector, overcoming present restrictions and unlocking new potential. This section explores these critical areas, demonstrating their potential to improve precision medicine and contribute to more inclusive and effective healthcare solutions [74].

5.1. Advances in omics technologies and their applications

The fast development of omics technologies, including genomes, transcriptomics, proteomics, metabolomics, and epigenomics, is driving advancements in understanding the genetic basis of inherited disorders. Innovations in NGS technology have greatly decreased prices and enhanced the efficiency of whole-genome and whole-exome sequencing, enabling the thorough investigation of genetic variations involved in hereditary illnesses. Single-cell genomics has further strengthened this understanding by showing cell-specific mutations, offering insights into disease heterogeneity and development [75]. Emerging omics domains, such as spatial transcriptomics and integrated multi-omics, will undoubtedly play a crucial role in increasing precision medicine. Spatial transcriptomics, for example, provides gene expression mapping within tissue architecture, giving a more nuanced knowledge of hereditary disorders such as CF and SCA at the tissue level. Similarly, multi-omics approaches that integrate data from different biological layers provide a holistic picture of disease mechanisms, enabling the identification of novel biomarkers and therapy targets. In addition to diagnostic achievements, omics technologies are transforming therapeutic strategies [76]. For instance, transcriptomics and proteomics are utilized to construct personalized drugs targeting specific biological processes. Moreover, findings in epigenomics are shedding light on the reversible nature of some epigenetic alterations, paving the way for epigenetic treatments that could modify sickness outcomes. To properly use these technologies, continual innovation in bioinformatics tools and analytical approaches will be necessary to handle and interpret the extensive data created by omics investigations [60].

Integrating omics technologies into precision medicine advances understanding of genetic abnormalities and contributes to sustainable development by enabling more efficient, tailored healthcare treatments. Multi-omics methods, comprising genomes, transcriptomics, proteomics, and metabolomics, enable early disease identification, minimizing the need for invasive procedures and costly late-stage treatments. These technologies promote sustainable healthcare systems by maximizing resource allocation and avoiding trial-and-error procedures in medication development. Furthermore, omics in precision medicine can help bridge healthcare gaps by fostering the development of affordable, accessible diagnostic tools and medicines, thereby increasing global health equity [60].

5.2. Potential for AI-driven predictive models in hereditary disease management

AI has emerged as a transformative tool in precision medicine, notably in treating genetic illnesses. Integrating ML and deep learning algorithms with genetic and clinical data can increase disease prediction, diagnosis, and therapy planning. Predictive AI-driven algorithms may examine huge, multidimensional information to identify patterns and linkages sometimes undetected by normal analytical approaches. One proposed use of AI is the production of polygenic risk scores (PRS), which assess an individual's susceptibility to hereditary diseases by evaluating the cumulative influence of genetic mutations. PRS models, when linked with clinical and lifestyle data, can provide a more detailed risk assessment, enabling early interventions and individualized treatment options. Additionally, AI is being applied to improve variant interpretation by prioritizing dangerous variants and minimizing false-positive findings, thereby enhancing the accuracy of genetic testing.

AI-driven models also hold the promise of boosting therapeutic decision-making. By analyzing multi-omics data, AI can predict individual responses to specific treatments, enabling the development of personalized therapies. For instance, AI algorithms can optimize lipid-lowering medication regimens based on a patient's genetic profile and clinical history in situations like FH. Beyond prediction, explainable AI frameworks are being researched to enhance the interpretability of AI outputs, guaranteeing that physicians can reliably integrate these insights into clinical practice [77]. However, successful AI use in hereditary disease treatment requires addressing key challenges, including the need for high-quality training datasets, reducing algorithmic bias, and establishing ethical guidelines for data use. Collaboration among AI developers, geneticists, and physicians will be crucial to overcome these constraints and realize the full potential of AI-driven precision medicine [78].

5.3. Development of equitable healthcare policies for precision medicine

The promise of precision medicine to revolutionize hereditary disease care can only be fulfilled if fair access to its advantages is ensured. Developing healthcare policies that address gaps in access to genetic testing, novel medicines, and personalized treatment is a vital priority. Current discrepancies are generally founded in socioeconomic, geographical, and systemic barriers that limit access to and the affordability of precision medicine for underrepresented people. Equitable healthcare policies must prioritize the engagement of different groups in genetic research and clinical trials. Underrepresentation of diverse ethnic and racial groups in genomic databases can lead to bias in variant interpretation and hinder the effectiveness of precision medicine for these populations. Policy measures should demand the diversification of genetic datasets to ensure that all persons benefit fairly from developments in hereditary disease management [49]. Furthermore, the expense of genetic testing and precision medications remains a substantial barrier for many families. Policies that provide subsidies or insurance coverage for these services are crucial for easing financial constraints and enhancing

Table 4. Advances in emerging technologies and their applications in hereditary disease management

Technology	Advances	Potential applications in hereditary disease management
Artificial intelligence (AI)	Development of predictive models, explainable AI, and federated learning frameworks	- Early detection of at-risk individuals using predictive risk scores - Optimization of treatment options based on patient-specific genetic data
Genomics (next-generation sequencing)	Enhanced speed, accuracy, and cost-effectiveness of genome and exome sequencing	- Comprehensive mutation profiling in inherited disorders - Identification of uncommon genetic variations leading to disease
Transcriptomics	Single-cell and spatial transcriptomics enabling precise gene expression mapping	- Identification of dysregulated pathways in inherited diseases - Development of targeted therapeutics
Proteomics	Advances in mass spectrometry and protein interaction analysis	- Discovery of protein biomarkers for early diagnosis and therapeutic targets
Epigenomics	High-resolution mapping of methylation patterns and chromatin accessibility	- Elucidation of epigenetic contributions to hereditary diseases - Personalized epigenetic therapies

accessibility. Governments and healthcare institutions must also invest in the infrastructure to deliver precision medicine, such as genetic counseling services and advanced testing facilities, in rural and low-resource areas. Another key component of policy development is resolving ethical problems associated with genetic privacy and bias. Comprehensive legal frameworks must be developed to shield individuals from the use of genetic information by employers, insurance, and other entities. These regulations should also govern data-sharing protocols to ensure that genetic information is used effectively while supporting research and innovation [78]. Lastly, public awareness and education campaigns should be linked to healthcare policies to enable individuals and families to make educated decisions concerning genetic testing and precision medicine. By increasing trust and engagement, these programs can bridge the gap between scientific findings and real-world applications, ensuring that the benefits of precision medicine extend to all.

The future of precision medicine in hereditary disease treatment lies at the intersection of technological innovation, AI-driven insights, and equitable policy frameworks. Advances in omics technologies and AI can transform our understanding of treating genetic disorders. At the same time, equitable healthcare policies are vital to ensure that these breakthroughs benefit all individuals and families. By tackling the difficulties and harnessing these opportunities, precision medicine can continue to drive progress toward improved health outcomes and a more equitable healthcare system [79]. Table 4 outlines key technological advances and their potential applications in the management of hereditary diseases. It highlights how innovations such as AI, genomics, transcriptomics, proteomics, and epigenomics contribute to early diagnosis, personalized treatment, and a deeper understanding of disease mechanisms (sources: ClinicalTrials.gov and PubMed-indexed studies published between 2013 and 2023).

5.4. Challenges in multi-omics analysis

One of the primary obstacles in multi-omics research is computational complexity, as combining multiple omics datasets produces vast amounts of high-dimensional data. The storage, processing, and analysis of such enormous datasets require robust computational infrastructure, including high-performance computing clusters and cloud-based solutions. Optimizing algorithms for effective data processing and ensuring scalability remain significant hurdles. Developing innovative bioinformatics tools capable of managing complex multi-omics data while keeping accuracy and speed is crucial for enhancing this discipline [80]. Another critical challenge is multidisciplinary bottlenecks, as multi-omics research requires competence across multiple domains, including genomics, bioinformatics, AI, and systems biology. However, the mismatch between biological and computational knowledge often limits advancement. Researchers with solid experience in genomics may lack skills in ML and data analytics. At the same time, computer scientists can find it tough to appreciate the biological meaning of omics data. Addressing this gap involves expanded multidisciplinary training programs, increased collaboration between biologists and data scientists, and the creation of user-friendly analytical tools that do not require substantial coding skills [81].

Reproducibility challenges can provide a substantial hurdle due to batch effects and technical variability inherent in multi-omics investigations. Differences in sample preparation, sequencing platforms, and data collection methodologies can lead to inconsistencies, making it difficult to compare results across projects. Researchers must use strict normalization techniques, establish standardized workflows, and maintain robust quality control measures to avoid these issues. Building harmonized multi-omics databases and implementing FAIR (Findable, Accessible, Interoperable, and Reusable) data principles might improve data reproducibility and permit more accurate cross-study comparisons [82].

5.5. Advancing scientific understanding and translational implications

The findings of this review show the transformative potential of precision medicine in changing the management of genetic disorders through the integration of genomic science, data analytics, and tailored care strategies. By combining evidence across numerous illnesses, such as CF, SCA, and FH, this review highlights how precision medicine has developed from theoretical notions to real clinical applications [83]. The use of CFTR modulators, PCSK9 inhibitors, and gene-editing techniques like CRISPR-Cas9 highlights the particular processes that can be addressed when therapies are guided by molecular pathology. These advances strengthen scientific understanding by illustrating how stratified medicine can improve illness outcomes through early diagnosis, focused therapy, and tailored treatment strategies [84]. Additionally, the integration of emerging technologies, including multi-omics platforms, spatial transcriptomics, and AI, enables greater insights into disease heterogeneity, underlying mechanisms, and patient-specific responses to medication. This knowledge broadens the traditional scope of medical genetics and underscores the necessity of systems biology techniques in translational medicine [85].

From a clinical standpoint, the study stresses the expanding importance of genetic screening programs for early risk detection, pharmacogenomic profiling for medication optimization, and cascade testing to support family-based treatments. These findings underline the need of incorporating precision medicine into routine care pathways, particularly for high-risk groups where timely intervention can reduce disease progression and increase long-term outcomes [86]. In terms of policy, embracing precision medicine requires robust health system structures that provide fair access to modern diagnostics and targeted therapies. Policymakers must address gaps in genetic infrastructure, lobby for data privacy rules, and encourage cross-sector cooperation to facilitate the clinical implementation of personalized medicine [87]. Additionally, creating national and regional guidelines for the use of genetic data in clinical decision-making will be crucial to ensure the ethical and uniform application of this data across healthcare settings. By highlighting these translational implications, the study contributes not only to academic discourse but also to the actual integration of precision medicine into public health and clinical practice [88].

6. Conclusion

The introduction of precision medicine has changed the management of hereditary disorders, enabling previously impossible options to adapt medicines to each patient's unique genetic makeup. Its influence on family health is remarkable, as it allows for early diagnosis, individualized therapeutic interventions, and preventive measures for at-risk family members. Advances like mutation-specific medicines for CF and FH, as well as gene-editing techniques like CRISPR-Cas9 for SCA, illustrate the revolutionary promise of precision medicine. These advances enhance therapeutic outcomes and improve the quality of life for patients and their families, ultimately reducing the burden of inherited illnesses across generations. Beyond its therapeutic benefits, precision medicine has transformed our understanding of genetic illnesses through insights from multi-omics technology, AI-driven predictive models, and genomic data. This holistic approach provides a deeper understanding of sickness mechanisms, enabling more effective interventions and ushering in a new era of family-centered healthcare. However, these transformative achievements are not without their challenges. Barriers such as inequitable access to genetic testing, the high cost of precision medications, and concerns about genetic privacy and discrimination continue to impede the full realization of precision medicine's potential. To solve these problems, joint efforts across scientific, medical, and policymaking sectors are needed. Governments, healthcare institutions, and research organizations must work to offer equal access to precision medicine for all populations, particularly underserved and marginalized groups. Investments in public awareness campaigns, genetic counseling infrastructure, and genomic education are vital for empowering individuals and families to make educated decisions regarding their health. Concurrently, robust ethical frameworks must be established to protect genetic privacy and build trust in precision medicine technologies. Expanding access to precision medicine requires innovation across research, healthcare delivery systems, and policy. Multi-stakeholder collaborations comprising doctors, academics, legislators, and patient advocacy groups are vital to addressing these difficulties. By pooling resources and knowledge, such collaborations can bridge accessibility gaps, address ethical concerns, and drive the implementation of precision medicine in clinical practice worldwide.

Ethical Statement

This study does not contain any studies with human or animal subjects performed by any of the authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest to this work.

Data Availability Statement

The data that support this work are available upon reasonable request to the corresponding author.

Author Contribution Statement

Rufus Oluwagbemileke Ajayi: Conceptualization, Writing – original draft, Writing – review & editing. **Oluwafikayo Seun Adeyemi-Benson:** Conceptualization, Writing – original draft. **Oluwateniola Ajoke Adeyemi-Benson:** Methodology, Project administration. **Taiwo Temitope Ogunjobi:** Methodology, Writing – review & editing. **Onyeka Mary Ukpoju-Ebonyi:** Investigation. **Jean-Marie Akor Ebonyi:** Investigation.

References

[1] Gomes, P., Pietrabissa, G., Silva, E. R., Silva, J., Matos, P. M., Costa, M. E., . . . , & Sales, C. M. (2022). Family adjustment to hereditary cancer syndromes: A systematic review. *International Journal of Environmental Research and Public Health*, *19*(3), 1603. https://doi.org/10.3390/ijerph19031603

[2] Nakato, R., & Sakata, T. (2021). Methods for ChIP-seq analysis: A practical workflow and advanced applications. *Methods*, *187*, 44–53. https://doi.org/10.1016/j.ymeth.2020.03.005

[3] Galvin, O., Chi, G., Brady, L., Hippert, C., del Valle Rubido, M., Daly, A., & Michaelides, M. (2020). The impact of inherited retinal diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a cost-of-illness perspective. *Clinical Ophthalmology*, *14*, 707–719. https://doi.org/10.2147/OPTH.S241928

[4] Strianese, O., Rizzo, F., Ciccarelli, M., Galasso, G., D'Agostino, Y., Salvati, A., . . . , & Rusciano, M. R. (2020). Precision and personalized medicine: How genomic approach improves the management of cardiovascular and neurodegenerative disease. *Genes*, *11*(7), 747. https://doi.org/10.3390/genes11070747

[5] Ontario Health (Quality). (2022). Genetic testing for familial hypercholesterolemia: Health technology assessment. *Ontario Health Technology Assessment Series*, *22*(3), 1–155. https://pmc.ncbi.nlm.nih.gov/articles/PMC9470216/

[6] Binnie, A., Fernandes, E., Almeida-Lousada, H., de Mello, R. A., & Castelo-Branco, P. (2021). CRISPR-based strategies in infectious disease diagnosis and therapy. *Infection*, *49*(3), 377–385. https://doi.org/10.1007/s15010-020-01554-w

[7] Manchia, M., Pisanu, C., Squassina, A., & Carpiniello, B. (2020). Challenges and future prospects of precision medicine in

psychiatry. *Pharmacogenomics and Personalized Medicine*, *13*, 127–140. https://doi.org/10.2147/pgpm.s198225

[8] Vadapalli, S., Abdelhalim, H., Zeeshan, S., & Ahmed, Z. (2022). Artificial intelligence and machine learning approaches using gene expression and variant data for personalized medicine. *Briefings in Bioinformatics*, *23*(5), bbac191. https://doi.org/10.1093/bib/bbac191

[9] Dhal, S., Khairari, K., Thatoi, P., Selvarathinam, A. L. X. R. A., & Rout, S. S. (2024). Economic impact of AI-driven precision medicine (studying the economic implications of AI-powered precision medicine approaches, including how personalized treatments can influence healthcare spending, patient outcomes, and overall system efficiency). *International Journal for Multidisciplinary Research*, *6*(5), 1–16. https://doi.org/10.36948/ijfmr.2024.v06i05.27789

[10] Fu, Q., Hu, L., Shen, T., Yang, R., & Jiang, L. (2022). Recent advances in gene therapy for familial hypercholesterolemia: An update review. *Journal of Clinical Medicine*, *11*(22), 6773. https://doi.org/10.3390/jcm11226773

[11] Heneghan, M., Southern, K. W., Murphy, J., Sinha, I. P., & Nevitt, S. J. (2023). Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). *Cochrane Database of Systematic Reviews*, (11), CD010966. https://doi.org/10.1002/14651858.cd010966.pub4

[12] Dagenais, R. V. E., Su, V. C., & Quon, B. S. (2020). Real-world safety of CFTR modulators in the treatment of cystic fibrosis: A systematic review. *Journal of Clinical Medicine*, *10*(1), 23. https://doi.org/10.3390/jcm10010023

[13] Denny, J. C., & Collins, F. S. (2021). Precision medicine in 2030—Seven ways to transform healthcare. *Cell*, *184*(6), 1415–1419. https://doi.org/10.1016/j.cell.2021.01.015.

[14] Sergeev, V., Chou, F. Y., Lam, G. Y., Hamilton, C. M., Wilcox, P. G., & Quon, B. S. (2020). The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. *Annals of the American Thoracic Society*, *17*(2), 147–154. https://doi.org/10.1513/annalsats.201909-671cme

[15] Shteinberg, M., & Taylor-Cousar, J. L. (2020). Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. *European Respiratory Review*, *29*(155), 190112. https://doi.org/10.1183/16000617.0112-2019

[16] Habib, A. R. R., Kajbafzadeh, M., Desai, S., Yang, C. L., Skolnik, K., & Quon, B. S. (2019). A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis. *Scientific Reports*, *9*(1), 7234. https://doi.org/10.1038/s41598-019-43652-2

[17] Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., . . . , & Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. *New England Journal of Medicine*, *384*(3), 252–260. https://doi.org/10.1056/nejmoa2031054

[18] Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., . . . , & Bauer, D. E. (2019). Highly efficient therapeutic gene editing of human hematopoietic stem cells. *Nature Medicine*, *25*(5), 776–783. https://doi.org/10.1038/s41591-019-0401-y

[19] Ceglie, G., Lecis, M., Canciani, G., Algeri, M., & Frati, G. (2023). Genome editing for sickle cell disease: Still time to correct? *Frontiers in Pediatrics*, *11*, 1249275. https://doi.org/10.3389/fped.2023.1249275

[20] Park, S. H., Lee, C. M., Dever, D. P., Davis, T. H., Camarena, J., Srifa, W., . . . , & Bao, G. (2019). Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. *Nucleic Acids Research*, *47*(15), 7955–7972. https://doi.org/10.1093/nar/gkz475

[21] Kantor, A., McClements, M. E., & MacLaren, R. E. (2020). CRISPR-Cas9 DNA base-editing and prime-editing. *International Journal of Molecular Sciences*, *21*(17), 6240. https://doi.org/10.3390/ijms21176240

[22] Giner, G., Ikram, S., Herold, M. J., & Papenfuss, A. T. (2023). A systematic review of computational methods for designing efficient guides for CRISPR DNA base editor systems. *Briefings in Bioinformatics*, *24*(4), bbad205. https://doi.org/10.1093/bib/bbad205

[23] Goel, R. (2024). CRISPR/Cas9-mediated genome editing: From basic research to gene therapy. *International Journal of Research in Medical Sciences*, *12*(6), 2200–2211. https://doi.org/10.18203/2320-6012.ijrms20241589

[24] Ghasempour, G., Zamani-Garmsiri, F., Shaikhnia, F., Soleimani, A. A., Hosseini Fard, S. R., Leila, J., . . . , & Najafi, M. (2024). Efficacy and safety of alirocumab and evolocumab as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in familial hypercholesterolemia: A systematic review and meta-analysis. *Current Medicinal Chemistry*, *31*(2), 223–241. https://doi.org/10.2174/0929867330666230228120601

[25] Siemens, R., Pryjma, M., Buchkowsky, S., & Barry, A. R. (2024). Real-world effectiveness of monoclonal antibody inhibitors of PCSK 9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *44*(9), 730–737. https://doi.org/10.1002/phar.4609

[26] Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J., Rubba, P., . . . , & Gaudet, D. (2020). Evinacumab for homozygous familial hypercholesterolemia. *New England Journal of Medicine*, *383*(8), 711–720. https://doi.org/10.1056/nejmoa2004215

[27] Tischler, J., Crew, K. D., & Chung, W. K. (2019). Cases in precision medicine: The role of tumor and germline genetic testing in breast cancer management. *Annals of Internal Medicine*, *171*(12), 925–930. https://doi.org/10.7326/m18-2417

[28] Pitini, E., D'Andrea, E., Rosso, A., Massimi, A., Unim, B., de Vito, C., . . . , & Villari, P. (2019). Genetic services for hereditary cancer: A systematic review of patient reported outcomes studies. *European Journal of Public Health*, *29*(Supplement_4), ckz186.380. https://doi.org/10.1093/eurpub/ckz186.380

[29] Tada, H., Kawashiri, M. A., Nohara, A., Sekiya, T., Watanabe, A., & Takamura, M. (2024). Genetic counseling and genetic testing for familial hypercholesterolemia. *Genes*, *15*(3), 297. https://doi.org/10.3390/genes15030297

[30] Yeates, L., McEwen, A., & Ingles, J. (2020). What do we do and how do we do it? Assessing genetic counselling in the modern era. *European Journal of Human Genetics*, *28*(9), 1137–1138. https://doi.org/10.1038/s41431-020-0628-6

[31] Morales, A., Goehringer, J., & Sanoudou, D. (2023). Evolving cardiovascular genetic counseling needs in the era of precision medicine. *Frontiers in Cardiovascular Medicine*, *10*, 1161029. https://doi.org/10.3389/fcvm.2023.1161029

[32] Campacci, N., Grasel, R. S., Galvão, H. D. C. R., Garcia, L. F., Carvalho Ribeiro, P., Pereira, K. F. D. J. D. S., . . . , & Palmero, E. I. (2024). The history of families at-risk for hereditary breast and ovarian cancer: What are the impacts of genetic counseling and testing? *Frontiers in Psychology*, *15*, 1306388. https://doi.org/10.3389/fpsyg.2024.1306388

[33] Brown, E. E. (2021). The genetic counselor's role in management of patients with dyslipidemia. *Current Opinion in Lipidology*, *32*(2), 83–88. https://doi.org/10.1097/mol.0000000000000732
[34] Ahmed, Z. (2020). Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. *Human Genomics*, *14*(1), 35. https://doi.org/10.1186/s40246-020-00287-z
[35] Rabinowitz, T., Polsky, A., Golan, D., Danilevsky, A., Shapira, G., Raff, C., . . . , & Shomron, N. (2019). Bayesian-based noninvasive prenatal diagnosis of single-gene disorders. *Genome Research*, *29*(3), 428–438. https://doi.org/10.1101/gr.235796.118
[36] Bowen, C. M., Demarest, K., Vilar, E., & Shah, P. D. (2024). Novel cancer prevention strategies in individuals with hereditary cancer syndromes: Focus on *BRCA1, BRCA2*, and Lynch Syndrome. *American Society of Clinical Oncology Educational Book*, *44*(3), e433576. https://doi.org/10.1200/edbk_433576
[37] Pedrazzani, C., Caiata-Zufferey, M., Kaiser-Grolimund, A., Bürki, N., Pagani, O., & Katapodi, M. C. (2019). Communication of genetic information to family members in hereditary cancers and healthcare providers' role. *Annals of Oncology*, *30*, v848. https://doi.org/10.1093/annonc/mdz277.008
[38] Demko, Z., Prigmore, B., & Benn, P. (2022). A critical evaluation of validation and clinical experience studies in non-invasive prenatal testing for trisomies 21, 18, and 13 and monosomy X. *Journal of Clinical Medicine*, *11*(16), 4760. https://doi.org/10.3390/jcm11164760
[39] Saba, L., Maindarkar, M., Johri, A. M., Mantella, L., Laird, J. R., Khanna, N. N., . . . , & Suri, J. S. (2024). UltraAIGenomics: Artificial intelligence-based cardiovascular disease risk assessment by fusion of ultrasound-based Radiomics and genomics features for preventive, personalized and precision medicine: A narrative review. *Reviews in Cardiovascular Medicine*, *25*(5), 184. https://doi.org/10.31083/j.rcm2505184
[40] Smit, A. K., Reyes-Marcelino, G., Keogh, L., Cust, A. E., & Newson, A. J. (2021). 'There is a lot of good in knowing, but there is also a lot of downs': Public views on ethical considerations in population genomic screening. *Journal of Medical Ethics*, *47*(12), e28. https://doi.org/10.1136/medethics-2019-105934
[41] Gandhi, A., & Elsea, S. H. (2023). Insights in neurogenomics: 2022. *Frontiers in Genetics*, *14*, 1252582. https://doi.org/10.3389/fgene.2023.1252582
[42] Soo, A. K. S., Ferrini, A., & Kurian, M. A. (2021). Precision medicine for genetic childhood movement disorders. *Developmental Medicine & Child Neurology*, *63*(8), 925–933. https://doi.org/10.1111/dmcn.14869
[43] Branje, S., Geeraerts, S., de Zeeuw, E. L., Oerlemans, A. M., Koopman-Verhoeff, M. E., Schulz, S., . . . , & Boomsma, D. I. (2020). Intergenerational transmission: Theoretical and methodological issues and an introduction to four Dutch cohorts. *Developmental Cognitive Neuroscience*, *45*, 100835. https://doi.org/10.1016/j.dcn.2020.100835
[44] Kendler, K. S., Ohlsson, H., Sundquist, J., & Sundquist, K. (2024). The impact of family-genetic risk scores on social functioning in individuals affected with six major psychiatric and substance use disorders in a Swedish National Sample. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, *195*(8), e32996. https://doi.org/10.1002/ajmg.b.32996
[45] Baroutsou, V., Underhill-Blazey, M. L., Appenzeller-Herzog, C., & Katapodi, M. C. (2021). Interventions facilitating family communication of genetic testing results and cascade screening in hereditary breast/ovarian cancer or lynch syndrome: A systematic review and meta-analysis. *Cancers*, *13*(4), 925. https://doi.org/10.3390/cancers13040925
[46] Leaver, M., & Wells, D. (2020). Non-invasive preimplantation genetic testing (niPGT): The next revolution in reproductive genetics? *Human Reproduction Update*, *26*(1), 16–42. https://doi.org/10.1093/humupd/dmz033
[47] Shi, Y., Mota, N. R., Franke, B., & Sprooten, E. (2025). Genetic liability to major psychiatric disorders contributes to multi-faceted quality of life outcomes in children and adults. *Translational Psychiatry*, *15*(1), 232. https://doi.org/10.1038/s41398-025-03443-y
[48] Lehmann, L. S., Snyder Sulmasy, L., Burke, W., Opole, I. O., Deep, N. N., Abraham, G. M., . . . , & Prager, K. M. (2022). Ethical considerations in precision medicine and genetic testing in internal medicine practice: A position paper from the American College of Physicians. *Annals of Internal Medicine*, *175*(9), 1322–1323. https://doi.org/10.7326/M22-0743
[49] Caffrey, R. G. (2022). Advocating for equitable management of hereditary cancer syndromes. *Journal of Genetic Counseling*, *31*(3), 584–589. https://doi.org/10.1002/jgc4.1548
[50] Jonsson, J. J., & Stefansdottir, V. (2019). Ethical issues in precision medicine. *Annals of Clinical Biochemistry*, *56*(6), 628–629. https://doi.org/10.1177/0004563219870824
[51] Khan, A., Rogers, C. R., Kennedy, C. D., Lopez, A., & Jeter, J. (2022). Genetic evaluation for hereditary cancer syndromes among African Americans: A critical review. *The Oncologist*, *27*(4), 285–291. https://doi.org/10.1093/oncolo/oyab082
[52] Ekusai-Sebatta, D., Ocan, M., Singh, S., Kyaddondo, D., Akena, D., Nakalembe, L., . . . , & Mwaka, E. (2023). Data sharing practices in collaborative human genomic research in low-and middle-income countries: A systematic review protocol. *Plos One*, *18*(11), e0292996. https://doi.org/10.1371/journal.pone.0292996
[53] Lopes-Pacheco, M. (2020). CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine. *Frontiers in Pharmacology*, *10*, 1662. https://doi.org/10.3389/fphar.2019.01662
[54] Papademetriou, V., Stavropoulos, K., Papadopoulos, C., Koutsampasopoulos, K., Dimitriadis, K., & Tsioufis, K. (2018). Role of PCSK9 inhibitors in high risk patients with dyslipidemia: Focus on familial hypercholesterolemia. *Current Pharmaceutical Design*, *24*(31), 3647–3653. https://doi.org/10.2174/1381612824666181010124657
[55] Reopell, L., Nolan, T. S., Gray, D. M., Williams, A., Brewer, L. C., Bryant, A. L., . . . , & Joseph, J. J. (2023). Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions—A report from the "Health Equity through Diversity" seminar series. *PLoS One*, *18*(2), e0281940. https://doi.org/10.1371/journal.pone.0281940
[56] Kamga, K. K., Fonkam, M. P., Nguefack, S., & Wonkam, A. (2024). *Navigating the genetic frontier for the integration of genetic services into African Healthcare Systems: A scoping review*. Research Square. https://doi.org/10.21203/rs.3.rs-3978686/v1
[57] Badola, S., & Zettler, B. (2022). The importance of genomics diversity in research. *Journal of Student Research*, *11*(1), 1–11. https://doi.org/10.47611/jsrhs.v11i1.2334
[58] Ogunjobi, T. T., Ohaeri, P. N., Akintola, O. T., Atanda, D. O., Orji, F. P., Adebayo, J. O., . . . , & Adedeji, O. O. (2024). Bioinformatics applications in chronic diseases: A comprehensive review of genomic, transcriptomics, proteomic, metabolomics, and

machine learning approaches. *Medinformatics*. Advance online publication. https://doi.org/10.47852/bonviewMEDIN42022335
[59] Zeggini, E., Gloyn, A. L., Barton, A. C., & Wain, L. V. (2019). Translational genomics and precision medicine: Moving from the lab to the clinic. *Science*, *365*(6460), 1409–1413. https://doi.org/10.1126/science.aax4588
[60] Adeyanju, S. A., & Ogunjobi, T. T. (2024). Machine learning in genomics: Applications in whole genome sequencing, whole exome sequencing, single-cell genomics, and spatial transcriptomics. *Medinformatics*. Advance online publication. https://doi.org/10.47852/bonviewMEDIN42024120
[61] Tang, L. F., Xu, A., & Liu, K. (2023). Pharmacogenomics-based individualized treatment of hypertension in preterm infants: A case report and review of the literature. *World Journal of Clinical Cases*, *11*(30), 7440–7449. https://doi.org/10.12998/wjcc.v11.i30.7440
[62] Zhang, H., Klareskog, L., Matussek, A., Pfister, S. M., & Benson, M. (2019). Translating genomic medicine to the clinic: Challenges and opportunities. *Genome Medicine*, *11*(1), 9. https://doi.org/10.1186/s13073-019-0622-1
[63] Costa, A., Merchant, A., Lopes, M. F., Konopko, M., Cardoso, M. L., Sitjà, X., . . . , & Vicente, A. (2022). Key issues for implementation of genomics in healthcare: A policy brief. *European Journal of Public Health*, *32*(Supplement_3), ckac131.022. https://doi.org/10.1093/eurpub/ckac131.022
[64] Casolino, R., Beer, P. A., Chakravarty, D., Davis, M. B., Malapelle, U., Mazzarella, L., . . . , & Biankin, A. V. (2024). Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. *CA: A Cancer Journal for Clinicians*, *74*(3), 264–285. https://doi.org/10.3322/caac.21825
[65] Vavekanand, R. (2024). Data security and privacy in genomics research: A comparative analysis to protect confidentiality. *Studies in Medical and Health Sciences*, *1*(1), 23–31. https://doi.org/10.48185/smhs.v1i1.1158
[66] Botkin, J. R. (2020). Informed consent for genetic and genomic research. *Current Protocols in Human Genetics*, *108*(1), e104. https://doi.org/10.1002/cphg.104
[67] Tiller, J., Morris, S., Rice, T., Barter, K., Riaz, M., Keogh, L., . . . , & Lacaze, P. (2020). Genetic discrimination by Australian insurance companies: A survey of consumer experiences. *European Journal of Human Genetics*, *28*(1), 108–113. https://doi.org/10.1038/s41431-019-0426-1
[68] Chapman, C. R., Mehta, K. S., Parent, B., & Caplan, A. L. (2020). Genetic discrimination: Emerging ethical challenges in the context of advancing technology. *Journal of Law and the Biosciences*, *7*(1), lsz016. https://doi.org/10.1093/jlb/lsz016
[69] Phillips, A., Borry, P., van Hoyweghen, I., & Vears, D. F. (2021). Disclosure of genetic information to family members: A systematic review of normative documents. *Genetics in Medicine*, *23*(11), 2038–2046. https://doi.org/10.1038/s41436-021-01248-0
[70] McWhirter, R., Eckstein, L., Chalmers, D., Critchley, C., Nielsen, J., Otlowski, M., & Nicol, D. (2020). A scenario-based methodology for analyzing the ethical, legal, and social issues in genomic data sharing. *Journal of Empirical Research on Human Research Ethics*, *15*(4), 355–364. https://doi.org/10.1177/1556264620920460
[71] Stiles, D., & Appelbaum, P. S. (2019). Cases in precision medicine: Concerns about privacy and discrimination after genomic sequencing. *Annals of Internal Medicine*, *170*(10), 717–721. https://doi.org/10.7326/M18-2666
[72] Grandhi, S. A., & Plotnick, L. (2022). Do I spit or do I pass? Perceived privacy and security concerns of direct-to-consumer genetic testing. *Proceedings of the ACM on Human-Computer Interaction, 6*(GROUP), 19. https://doi.org/10.1145/3492838
[73] Matranga, C. (2020). Family ties: The familial privacy implications of direct-to-consumer genetic testing. *Food and Drug Law Journal*, *75*(3), 456–486. https://doi.org/10.2139/ssrn.3533283
[74] García-Foncillas, J., Argente, J., Bujanda, L., Cardona, V., Casanova, B., Fernández-Montes, A., . . . , & Pérez Gómez, M. V. (2021). Milestones of precision medicine: An innovative, multidisciplinary overview. *Molecular Diagnosis & Therapy*, *25*(5), 563–576. https://doi.org/10.1007/s40291-021-00544-4
[75] Dar, M. A., Arafah, A., Bhat, K. A., Khan, A., Khan, M. S., Ali, A., . . . , & Rehman, M. U. (2023). Multiomics technologies: Role in disease biomarker discoveries and therapeutics. *Briefings in Functional Genomics*, *22*(2), 76–96. https://doi.org/10.1093/bfgp/elac017
[76] Temitope, O. T., Ifeoluwa, O. T., Adegbola, A. S., Oluwatosin, A. J., Daniel, A. A., Joy, N. A., . . . , & Goodluck, A. O. (2025). Epigenomic profiling in cancer: Techniques and therapeutic implications. *International Journal of Advanced Biological and Biomedical Research*, *13*(2), 90–116. https://doi.org/10.48309/IJABBR.2025.2035869.1534
[77] Schürch, M., Boos, L., Heinzelmann-Schwarz, V., Gut, G., Krauthammer, M., & Wicki, A. (2024). *Towards AI-based precision oncology: A machine learning framework for personalized counterfactual treatment suggestions based on multi-omics data*. arXiv.
[78] Esengoenuel, M., Marta, A., Beirao, J., Pires, I. M., & Cunha, A. (2022). A systematic review of artificial intelligence applications used for inherited retinal disease management. *Medicina*, *58*(4), 504. https://doi.org/10.3390/medicina58040504
[79] Bélisle-Pipon, J. C., Vayena, E., Green, R. C., & Cohen, I. G. (2019). Genetic testing, insurance discrimination and medical research: What the United States can learn from peer countries. *Nature Medicine*, *25*(8), 1198–1204. https://doi.org/10.1038/s41591-019-0534-z
[80] Dolan, D. D., Cho, M. K., & Lee, S. S. J. (2023). Innovating for a just and equitable future in genomic and precision medicine research. *The American Journal of Bioethics*, *23*(7), 1–4. https://doi.org/10.1080/15265161.2023.2215201
[81] Miao, Z., Humphreys, B. D., McMahon, A. P., & Kim, J. (2021). Multi-omics integration in the age of million single-cell data. *Nature Reviews Nephrology*, *17*(11), 710–724. https://doi.org/10.1038/s41581-021-00463-x
[82] Zhou, G., Ewald, J., & Xia, J. (2021). OmicsAnalyst: A comprehensive web-based platform for visual analytics of multi-omics data. *Nucleic Acids Research*, *49*(W1), W476–W482. https://doi.org/10.1093/nar/gkab394
[83] Goh, W. W. B., Wang, W., & Wong, L. (2017). Why batch effects matter in omics data, and how to avoid them. *Trends in Biotechnology*, *35*(6), 498–507. https://doi.org/10.1016/j.tibtech.2017.02.012
[84] Ahmed, Z. (2020). Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. *Human Genomics*, *14*(1), 35. https://doi.org/10.1186/s40246-020-00287-z
[85] Gu, B., Li, M., Li, D., & Huang, K. (2025). CRISPR-Cas9 targeting PCSK9: A promising therapeutic approach for atherosclerosis. *Journal of Cardiovascular Translational Research*, *18*(2), 424–441. https://doi.org/10.1007/s12265-024-10587-7

[86] Shao, Y., Lv, X., Ying, S., & Guo, Q. (2024). Artificial intelligence-driven precision medicine: Multi-omics and spatial multi-omics approaches in diffuse large B-cell lymphoma (DLBCL). *Frontiers in Bioscience-Landmark*, *29*(12), 404. https://doi.org/10.31083/j.fbl2912404

[87] Shen, E. C., Srinivasan, S., Passero, L. E., Allen, C. G., Dixon, M., Foss, K., . . . , & Roberts, M. C. (2022). Barriers and facilitators for population genetic screening in healthy populations: A systematic review. *Frontiers in Genetics*, *13*, 865384. https://doi.org/10.3389/fgene.2022.865384

[88] Ramaswami, R., Bayer, R., & Galea, S. (2018). Precision medicine from a public health perspective. *Annual Review of Public Health*, *39*(1), 153–168. https://doi.org/10.1146/annurev-publhealth-040617-014158

How to Cite: Ajayi, R. O., Adeyemi-Benson, O. S., Adeyemi-Benson, O. A., Ogunjobi, T. T., Ukpoju-Ebonyi, O. M., & Ebonyi, J.-M. A. (2025). The Role of Precision Medicine in Family Health: Tailoring Treatments for Hereditary Diseases. *Medinformatics*. https://doi.org/10.47852/bonviewMEDIN52025796